Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 4/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 5/20 | 0.34 |
| ▸ | PDE4A | P27815 | 4/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | PDE5A | O76074 | 1/20 | 0.34 |
| ▸ | PDE1A | P54750 | 1/20 | 0.34 |
| ▸ | PDE1B | Q01064 | 1/20 | 0.34 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.34 |
| ▸ | GPR6 | P46095 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | GBA1 | P04062 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.33 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6948732 | 0.83 | ALDH1A1 (0.36) | PDE4BPDE4DPDE4APDE4CALDH1A1 | |
| SCHEMBL5774974 | 0.83 | EGFR (0.44) | PDE4BPDE4DPDE4APDE4C | |
| SCHEMBL18305639 | 0.82 | GPR6 (0.36) | GPR6SLC6A9 | |
| SCHEMBL17844396 | 0.81 | GPR6 (0.40) | GPR6 | |
| SCHEMBL13914989 | 0.79 | GPR6 (0.36) | PDE4BGPR6SLC6A9 | |
| SCHEMBL17837908 | 0.77 | GPR119 (0.53) | PDE4BPDE4DPDE4APDE4CALDH1A1 | |
| SCHEMBL16935408 | 0.77 | NPY1R (0.36) | PDE4BSLC6A9 | |
| SCHEMBL19661664 | 0.77 | PTGS1 (0.35) | PTGS1PTGS2 | |
| SCHEMBL5773407 | 0.77 | IKBKB (0.36) | ALDH1A1CYP1A2CYP3A4CYP2C19CD274 | |
| SCHEMBL186585 | 0.76 | TRPV4 (0.52) | ALDH1A1CYP1A2CYP3A4KDM4EGBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1483257-B1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LTD (GB) | 2006-09-13 | — | — | EP | disclosed |
| US-6936619-B2 | Cardiovascular disorders; antilipemic agents; sexual disorders | PFIZER, INC. (US) | 2005-08-30 | — | — | US | disclosed |
| EP-1483257-A1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | Pfizer Limited (GB) | 2004-12-08 | — | — | EP | disclosed |
| US-20040029859-A1 | Compounds useful in therapy | PFIZER INC. | 2004-02-12 | — | — | US | disclosed |
| EP-0887344-B1 | Quinolines and quinazolines useful in therapy | PFIZER LTD (GB) | 2003-12-03 | — | — | EP | disclosed |
| WO-2003076427-A1 | QUINAZOLINE COMPOUNDS USEFUL IN THERAPY | PFIZER LIMITED (GB) | 2003-09-18 | — | — | WO | disclosed |
| US-6417194-B1 | TREATMENT OF BENIGN PROSTATIC HYPERPLASIA | PFIZER, INC. | 2002-07-09 | — | — | US | disclosed |
| US-6048864-A | Quinolines and quinazolines useful in therapy | PFIZER INC (US) | 2000-04-11 | — | — | US | disclosed |
| EP-0887344-A1 | Quinolines and quinazolines useful in therapy | Pfizer Limited (GB) | 1998-12-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040029859-A1 | Compounds useful in therapy | ADRA1D, HSD3B1, PTGER1 | PDE4B 1003/4885PDE4D 684/4885PDE4A 806/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.